Search results for "Lymphocyte Transfusion"

showing 10 items of 12 documents

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T …

2007

In allogeneic hematopoietic stem cell transplantation (AHSCT) graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect are closely but not invariably linked. Thus, harnessing donor lymphocyte mediated GVL immunity and separating it from GVHD is of particular interest. Based on results obtained in murine models we have explored the CD95-mediated activation-induced cell death (AICD) strategy to selectively deplete alloreactivity in human donor T lymphocytes in vitro. Following stimulation of CD3(+) T cells isolated from HLA-A* 0201-positive donors with HLA or minor histocompatibility antigen mismatched hematopoietic or nonhematopoietic cells in the presence of agonistic anti-CD…

AllodepletionLymphocyteApoptosisGraft vs Leukemia EffectHuman leukocyte antigenBiologyEpitopeLymphocyte DepletionImmune systemCell Line TumorMinor histocompatibility antigenmedicineCytotoxic T cellHumansTransplantation Homologousfas ReceptorTransplantationHematopoietic Stem Cell TransplantationFOXP3Hematologymedicine.anatomical_structureLymphocyte TransfusionImmunologyT cell depletionLymphocyte graft engineeringCD8Biology of Blood and Marrow Transplantation
researchProduct

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted al…

2009

Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day +60. A total of 13 patients received CD8(depl) DLI and 7 patients did not. All but one of the DLI patients converted to complete donor T-cell chimeras, whereas only one non-DLI patient converted spontaneously. DLI induced transient acute GVHD in five and extensive chronic GVHD in two patients. These data suggest the use of CD8(depl) DLI as an effective treatment for mixed TCC, partic…

CD4-Positive T-LymphocytesAntibodies NeoplasmLymphocytemedicine.medical_treatmentHematopoietic stem cell transplantation*Lymphocyte DepletionT-Lymphocyte SubsetsAlemtuzumabddc:616Transplantation Chimera/*immunologyHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.anatomical_structureCD52 AntigenLymphocyte TransfusionAlemtuzumabmedicine.drug*GlycoproteinsAdultCD52T cellAntibodies Monoclonal/therapeutic useAntineoplastic AgentsCD4-Positive T-Lymphocytes/*transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionAntigens CDAntigens NeoplasmmedicineAntibodies Neoplasm/therapeutic useHumans*Peripheral Blood Stem Cell TransplantationAgedCell ProliferationGlycoproteinsLymphocyte Transfusion/*methodsTransplantationPeripheral Blood Stem Cell TransplantationTransplantation Chimerabusiness.industryAntineoplastic Agents/therapeutic usemedicine.diseaseTransplantationGraft-versus-host disease*Antigens NeoplasmImmunology*Antigens CDbusinessCD8Bone marrow transplantation
researchProduct

Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo.

2004

Background: Interleukin 18 (IL-18) is a cytokine with pleiotropic activity that augments T helper 1 responses and cytotoxic activity of natural killer cells. Methods: To assess the function of IL-18 in vivo, we generated IL-18 transgenic (IL-18 Tg) mice under the control of a CD2 promoter/enhancer construct. Results: Macroscopically, IL-18 Tg mice showed reduced relative liver weight compared with wild-type littermates. TUNEL assays demonstrated increased hepatocyte apoptosis, and primary hepatocytes isolated from IL-18 Tg mice exhibited an increased spontaneous apoptosis rate. Furthermore, cross linking of Fas increased significantly the apoptosis rate in hepatocytes isolated from wild- ty…

Genetically modified mousemedicine.medical_specialtyTransgeneT-LymphocytesApoptosisMice TransgenicMice SCIDBiologyTransfectionTranslocation GeneticInterferon-gammaMiceIn vivoInternal medicinemedicineCytotoxic T cellAnimalsfas ReceptorL-SelectinCells CulturedLiver injuryTumor Necrosis Factor-alphaGastroenterologyInterleukin-18NF-kappa BOrgan Sizemedicine.diseaseAdoptive TransferEndocrinologymedicine.anatomical_structureLiverApoptosisHepatocyteLymphocyte TransfusionCancer researchHepatocytesInterleukin 18Gut
researchProduct

Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria.

2015

Human group 1 ILCs consist of at least three phenotypically distinct subsets, including NK cells, CD127(+) ILC1, and intraepithelial CD103(+) ILC1. In inflamed intestinal tissues from Crohn's disease patients, numbers of CD127(+) ILC1 increased at the cost of ILC3. Here we found that differentiation of ILC3 to CD127(+) ILC1 is reversible in vitro and in vivo. CD127(+) ILC1 differentiated to ILC3 in the presence of interleukin-2 (IL-2), IL-23, and IL-1β dependent on the transcription factor RORγt, and this process was enhanced in the presence of retinoic acid. Furthermore, we observed in resection specimen from Crohn's disease patients a higher proportion of CD14(+) dendritic cells (DC), whi…

Interleukin 2Receptors Retinoic AcidCellular differentiationCD14ImmunologyInterleukin-1betaRetinoic acidLipopolysaccharide Receptorschemical and pharmacologic phenomenaTretinoinMice SCIDBiologyInterleukin-12 Subunit p35Interleukin-7 Receptor alpha Subunitchemistry.chemical_compoundMiceIntestinal mucosaCrohn DiseaseMice Inbred NODmedicineImmunology and AllergyAnimalsHumansRetinoid X Receptor gammaLymphocytesIntestinal MucosaInterleukin-7 receptorCells CulturedMice KnockoutRetinoic Acid Receptor alphaInnate lymphoid cellvirus diseaseshemic and immune systemsCell DifferentiationDendritic CellsNuclear Receptor Subfamily 1 Group F Member 3Molecular biologyKiller Cells NaturalMice Inbred C57BLInfectious DiseaseschemistryLymphocyte TransfusionImmunologyInterleukin 12Interleukin-23 Subunit p19Interleukin-2medicine.drugImmunity
researchProduct

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth

2018

Abstract The Wnt/β-catenin pathway regulates T-cell functions, including the repression of effector functions to the advantage of memory development via Tcf1. In a companion study, we demonstrate that, in human cancers, Wnt3a/β-catenin signaling maintains tumor-infiltrating T cells in a partially exhausted status. Here, we have investigated the effects of Wnt3a neutralization in vivo in a mouse tumor model. Abundant Wnt3a was released, mostly by stromal cells, in the tumor microenvironment. We tested whether Wnt3a neutralization in vivo could rescue the effector capacity of tumor-infiltrating T cells, by administering an antibody to Wnt3a to tumor-bearing mice. This therapy restrained tumor…

Male0301 basic medicineCancer Researchanimal structuresStromal cellT cellmedicine.medical_treatmentImmunologyAdenocarcinomaCD8-Positive T-LymphocytesDendritic CellSettore MED/0403 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmunology; Cancer Research; Wnt; Beta-catenin.Cell Line TumorWnt3A ProteinmedicineAnimalsHumansWnt Signaling PathwayColonic NeoplasmTumor microenvironmentAnimalChemistryEffectorStromal CellWnt signaling pathwayCD8-Positive T-LymphocyteDendritic CellsImmunotherapyDendritic cellCell biologyMice Inbred C57BLbody regions030104 developmental biologymedicine.anatomical_structureLymphocyte Transfusion030220 oncology & carcinogenesisColonic Neoplasmsembryonic structuresImmunotherapyStromal CellsCD8HumanCancer Immunology Research
researchProduct

Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience

2016

Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant rel…

Malemedicine.medical_specialtyLymphocyte TransfusionAdolescentmedicine.medical_treatment03 medical and health sciences0302 clinical medicineRecurrenceGermanymedicineHumansProgenitor cellChildRetrospective StudiesTransplantationChemotherapybusiness.industryInfantRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsmedicine.diseaseTissue DonorsSurgeryTransplantationClinical trialsurgical procedures operativeGraft-versus-host diseaseChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisFemaleImmunotherapybusinessStem Cell Transplantation030215 immunologyBone Marrow Transplantation
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Primary in vivo T cell reactivity of NZB grafts in H-2 identical allogenic hosts.

1983

By means of the Simonson GVH-assay and the popliteal lymph node (PLN) assay, the T-cell reactivity of NZB mice against H-2 identical allogenic cells was investigated in vivo and compared to that of normal mice. None of the normal mice did react, but a highly significant NZB response could be demonstrated, which did not depend on differences in Mls antigens. These in vivo results extend previous findings of a T-cell hyperreactivity of NZB mice in primary in vitro reactions. They favour the possibility that the T-cell hyperreactivity might be relevant in vivo in facilitating autoimmune responses.

T-LymphocytesImmunologychemical and pharmacologic phenomenaAutoimmune responsesBiologySerologyAutoimmune DiseasesMinor Lymphocyte Stimulatory AntigensGraft vs Host ReactionMiceIn vivoImmunology and AllergyAnimalsLymphocytesMice Inbred BALB CMice Inbred NZBH-2 AntigensT cell reactivityHematologyOrgan SizeIn vitroTransplantationMice Inbred C57BLKineticsLiverMice Inbred DBALymphocyte TransfusionImmunologyPopliteal Lymph NodeSpleenImmunobiology
researchProduct